Clinical trial · Interventional
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
NCT00092001CI-TRIAL-00001733completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Sunitinib
Primary outcomes (1)
- measure
- Overall confirmed objective response rate (ORR)
- timeFrame
- From screening until at least 28 days beyond discontinuation of study treatment.
Secondary outcomes (5)
- measure
- Progression-free survival (PFS)
- timeFrame
- From screening until disease progression or discontinuation of study
- measure
- Time to progression (TTP)
- timeFrame
- From screening until disease progression or discontinuation of study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed advanced or metastatic Non-Small Cell Lung Cancer that cannot be cured with surgery, radiation, or combination thereof * No more than 2 prior chemotherapy treatments including treatment with a platinum containing therapy * Evidence of measurable disease by radiographic technique * Male or Female, 18 years or older * ECOG performance status of 0 or 1 * Resolution of all acute toxicities of prior therapies * Adequate organ function Exclusion Criteria: * Major surgery or radiation therapy within 4 weeks * Severe hemorrhage within 4 weeks * Previous treatment with anti-angiogenesis agents * Diagnosis of second malignancy within last five 5 years * History of or known brain metastases, spinal cord compression, or carcinomatous meningitis * Known HIV * Serious acute or chronic illness * Current treatment on another clinical trial * Pregnant or breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.